Journal of Gastroenterology

, Volume 46, Issue 3, pp 318–324

The long-term risk of gastric cancer after the successful eradication of Helicobacter pylori

  • Susumu Take
  • Motowo Mizuno
  • Kuniharu Ishiki
  • Tomowo Yoshida
  • Nobuya Ohara
  • Kenji Yokota
  • Keiji Oguma
  • Hiroyuki Okada
  • Kazuhide Yamamoto
Original Article—Alimentary Tract

Abstract

Background

We previously reported that eradication of Helicobacter pylori reduced the risk of developing gastric cancer in patients with peptic ulcer diseases. In the present study, we further followed up our patient group to investigate the occurrence and clinical features of gastric cancers that developed after cure of the infection.

Methods

Prospective post-eradication evaluations were conducted on 1674 consecutive patients who had received successful H. pylori eradication therapy. The patients had undergone endoscopic examination before eradication therapy to evaluate peptic ulcers, background gastric mucosal atrophy, and H. pylori infection. After confirmation of cure of the infection, follow-up endoscopy was performed yearly.

Results

The patients were followed for up to 14.1 years (a mean of 5.6 years). During the follow-up, gastric cancer developed in 28 of the 1674 patients as long as 13.7 years after the cure of H. pylori infection. The risk of developing gastric cancer was 0.30% per year. Histologically, 16 of the gastric cancers were the intestinal type and 12 were the diffuse type; the risk of each cancer type was 0.17 and 0.13% per year, respectively. There was no significant inflammatory cell infiltration in the background gastric mucosa at the time the cancers were recognized.

Conclusion

There is a risk of developing gastric cancer of both the intestinal and diffuse types even after the cure of H. pylori infection and extinction of gastric inflammation. It is important to inform patients about the risk of gastric cancer after eradication therapy and offer them surveillance endoscopy.

Keywords

Eradication therapy Gastric cancer Helicobacter pylori 

References

  1. 1.
    Infection with Helicobacter pylori. IARC Monogr Eval Carcinog Risks Hum 1994;61:177–240.Google Scholar
  2. 2.
    Blaser MJ. The bacteria behind ulcers. Sci Am. 1996;274:104–7.PubMedCrossRefGoogle Scholar
  3. 3.
    Uemura N, Okamoto S, Yamamoto S, Matsumura N, Yamaguchi S, Yamakido M, et al. Helicobacter pylori infection and the development of gastric cancer. N Engl J Med. 2001;345:784–9.PubMedCrossRefGoogle Scholar
  4. 4.
    Graham DY. Helicobacter pylori infection is the primary cause of gastric cancer. J Gastroenterol. 2000;35(Suppl 12):90–7.PubMedGoogle Scholar
  5. 5.
    Kikuchi S. Epidemiology of Helicobacter pylori and gastric cancer. Gastric Cancer. 2002;5:6–15.PubMedCrossRefGoogle Scholar
  6. 6.
    Sepulveda AR, Graham DY. Role of Helicobacter pylori in gastric carcinogenesis. Gastroenterol Clin North Am. 2002;31:517–35.PubMedCrossRefGoogle Scholar
  7. 7.
    Brenner H, Arndt V, Stegmaier C, Ziegler H, Rothenbacher D. Is Helicobacter pylori infection a necessary condition for noncardia gastric cancer? Am J Epidemiol. 2004;159:252–8.PubMedCrossRefGoogle Scholar
  8. 8.
    Graham DY, Shiotani A. The time to eradicate gastric cancer is now. Gut. 2005;54:735–8.PubMedCrossRefGoogle Scholar
  9. 9.
    Malfertheiner P, Sipponen P, Naumann M, Moayyedi P, Megraud F, Xiao SD, et al. Helicobacter pylori eradication has the potential to prevent gastric cancer: a state-of-the-art critique. Am J Gastroenterol. 2005;100:2100–15.PubMedCrossRefGoogle Scholar
  10. 10.
    Fuccio L, Zagari RM, Eusebi LH, Laterza L, Cennamo V, Ceroni L, et al. Meta-analysis: can Helicobacter pylori eradication treatment reduce the risk for gastric cancer? Ann Intern Med. 2009;151:121–8.PubMedGoogle Scholar
  11. 11.
    Uemura N, Mukai T, Okamoto S, Yamaguchi S, Mashiba H, Taniyama K, et al. Effect of Helicobacter pylori eradication on subsequent development of cancer after endoscopic resection of early gastric cancer. Cancer Epidemiol Biomarkers Prev. 1997;6:639–42.PubMedGoogle Scholar
  12. 12.
    Uemura N, Okamoto S. Effect of Helicobacter pylori eradication on subsequent development of cancer after endoscopic resection of early gastric cancer in Japan. Gastroenterol Clin North Am. 2000;29:819–27.PubMedCrossRefGoogle Scholar
  13. 13.
    Fukase K, Kato M, Kikuchi S, Inoue K, Uemura N, Okamoto S, et al. Effect of eradication of Helicobacter pylori on incidence of metachronous gastric carcinoma after endoscopic resection of early gastric cancer: an open-label, randomised controlled trial. Lancet. 2008;372:392–7.PubMedCrossRefGoogle Scholar
  14. 14.
    Wong BC, Lam SK, Wong WM, Chen JS, Zheng TT, Feng RE, et al. Helicobacter pylori eradication to prevent gastric cancer in a high-risk region of China: a randomized controlled trial. JAMA. 2004;291:187–94.PubMedCrossRefGoogle Scholar
  15. 15.
    Miyoshi M, Mizuno M, Ishiki K, Nagahara Y, Maga T, Torigoe T, et al. A randomized open trial for comparison of proton pump inhibitors, omeprazole versus rabeprazole, in dual therapy for Helicobacter pylori infection in relation to CYP2C19 genetic polymorphism. J Gastroenterol Hepatol. 2001;16:723–8.PubMedCrossRefGoogle Scholar
  16. 16.
    Adachi M, Mizuno M, Yokota K, Miyoshi M, Nagahara Y, Maga T, et al. Reinfection rate following effective therapy against Helicobacter pylori infection in Japan. J Gastroenterol Hepatol. 2002;17:27–31.PubMedCrossRefGoogle Scholar
  17. 17.
    Take S, Mizuno M, Ishiki K, Nagahara Y, Yoshida T, Inaba T, et al. Interleukin-1beta genetic polymorphism influences the effect of cytochrome P 2C19 genotype on the cure rate of 1-week triple therapy for Helicobacter pylori infection. Am J Gastroenterol. 2003;98:2403–8.PubMedGoogle Scholar
  18. 18.
    Ishiki K, Mizuno M, Take S, Nagahara Y, Yoshida T, Yamamoto K, et al. Helicobacter pylori eradication improves pre-existing reflux esophagitis in patients with duodenal ulcer disease. Clin Gastroenterol Hepatol. 2004;2:474–9.PubMedCrossRefGoogle Scholar
  19. 19.
    Take S, Mizuno M, Ishiki K, Nagahara Y, Yoshida T, Yokota K, et al. The effect of eradicating Helicobacter pylori on the development of gastric cancer in patients with peptic ulcer disease. Am J Gastroenterol. 2005;100:1037–42.PubMedCrossRefGoogle Scholar
  20. 20.
    Ishioka H, Mizuno M, Take S, Ishiki K, Nagahara Y, Yoshida T, et al. A better cure rate with 800 mg than with 400 mg clarithromycin regimens in one-week triple therapy for Helicobacter pylori infection in cigarette-smoking peptic ulcer patients. Digestion. 2007;75:63–8.PubMedCrossRefGoogle Scholar
  21. 21.
    Take S, Mizuno M, Ishiki K, Nagahara Y, Yoshida T, Yokota K, et al. Baseline gastric mucosal atrophy is a risk factor associated with the development of gastric cancer after Helicobacter pylori eradication therapy in patients with peptic ulcer diseases. J Gastroenterol. 2007;42(Suppl 17):21–7.PubMedCrossRefGoogle Scholar
  22. 22.
    Take S, Mizuno M, Ishiki K, Nagahara Y, Yoshida T, Yokota K, et al. Helicobacter pylori eradication may induce de novo, but transient and mild, reflux esophagitis: prospective endoscopic evaluation. J Gastroenterol Hepatol. 2009;24:107–13.PubMedCrossRefGoogle Scholar
  23. 23.
    Kimura K, Takemoto T. An endoscopic recognition of the atrophic border and its significance in chronic gastritis. Endoscopy. 1969;3:87–97.CrossRefGoogle Scholar
  24. 24.
    Sakaki N, Arakawa T, Katou H, Momma K, Egawa N, Kamisawa T, et al. Relationship between progression of gastric mucosal atrophy and Helicobacter pylori infection: retrospective long-term endoscopic follow-up study. J Gastroenterol. 1997;32:19–23.PubMedCrossRefGoogle Scholar
  25. 25.
    Ito S, Azuma T, Murakita H, Hirai M, Miyaji H, Ito Y, et al. Profile of Helicobacter pylori cytotoxin derived from two areas of Japan with different prevalence of atrophic gastritis. Gut. 1996;39:800–6.PubMedCrossRefGoogle Scholar
  26. 26.
    Satoh K, Kimura K, Taniguchi Y, Yoshida Y, Kihira K, Takimoto T, et al. Distribution of inflammation and atrophy in the stomach of Helicobacter pylori-positive and -negative patients with chronic gastritis. Am J Gastroenterol. 1996;91:963–9.PubMedGoogle Scholar
  27. 27.
    Nagahara Y, Mizuno M, Maga T, Ishiki K, Okuno T, Yoshida T, et al. Outcome of patients with inconsistent results from 13C-urea breath test and bacterial culture at the time of assessment of Helicobacter pylori eradication therapy in Japan. Hepatogastroenterology. 2003;50:1700–3.PubMedGoogle Scholar
  28. 28.
    Hamilton SR, Aaltonen LA, editors. Pathology and genetics of tumours of the digestive system. In: Kleihues P, Sobin LH, series editors. World Health Organization classification of tumours. Lyon: IARC Press; 2000.Google Scholar
  29. 29.
    Lauren P. The two histological main types of gastric carcinoma: diffuse and so-called intestinal-type carcinoma. Acta Pathol Microbiol Scand. 1965;64:31–49.PubMedGoogle Scholar
  30. 30.
    Dixon MF, Genta RM, Yardley JH, Correa P. Classification and grading of gastritis. The updated Sydney System. International Workshop on the Histopathology of Gastritis, Houston 1994. Am J Surg Pathol. 1996;20:1161–81.PubMedCrossRefGoogle Scholar
  31. 31.
    Japanese Gastric Cancer Association. Japanese classification of gastric carcinoma, 2nd English edition. Gastric Cancer 1998;1:10–24.Google Scholar
  32. 32.
    Takenaka R, Okada H, Kato J, Makidono C, Hori S, Kawahara Y, et al. Helicobacter pylori eradication reduced the incidence of gastric cancer, especially of the intestinal type. Aliment Pharmacol Ther. 2007;25:805–12.PubMedCrossRefGoogle Scholar
  33. 33.
    Ogura K, Hirata Y, Yanai A, Shibata W, Ohmae T, Mitsuno Y, et al. The effect of Helicobacter pylori eradication on reducing the incidence of gastric cancer. J Clin Gastroenterol. 2008;42:279–83.PubMedGoogle Scholar
  34. 34.
    Wu CY, Kuo KN, Wu MS, Chen YJ, Wang CB, Lin JT. Early Helicobacter pylori eradication decreases risk of gastric cancer in patients with peptic ulcer disease. Gastroenterology. 2009;137:1641–8. (e1-2).PubMedCrossRefGoogle Scholar
  35. 35.
    Yanaoka K, Oka M, Ohata H, Yoshimura N, Deguchi H, Mukoubayashi C, et al. Eradication of Helicobacter pylori prevents cancer development in subjects with mild gastric atrophy identified by serum pepsinogen levels. Int J Cancer. 2009;125:2697–703.PubMedCrossRefGoogle Scholar
  36. 36.
    Tucci A, Biasco G, Paparo GF. Effect of eradication of Helicobacter pylori in patients with fundic atrophic gastritis. N Engl J Med. 1997;336:957–8.PubMedCrossRefGoogle Scholar
  37. 37.
    Ohkusa T, Fujiki K, Takashimizu I, Kumagai J, Tanizawa T, Eishi Y, et al. Improvement in atrophic gastritis and intestinal metaplasia in patients in whom Helicobacter pylori was eradicated. Ann Intern Med. 2001;134:380–6.PubMedGoogle Scholar
  38. 38.
    Itzkowitz SH, Yio X. Inflammation and cancer IV. Colorectal cancer in inflammatory bowel disease: the role of inflammation. Am J Physiol Gastrointest Liver Physiol. 2004;287:G7–17.PubMedCrossRefGoogle Scholar
  39. 39.
    Macarthur M, Hold GL, El-Omarc EM. Inflammation and cancer II. Role of chronic inflammation and cytokine gene polymorphisms in the pathogenesis of gastrointestinal malignancy. Am J Physiol Gastrointest Liver Physiol. 2004;286:G515–20.PubMedCrossRefGoogle Scholar
  40. 40.
    Rogers AB, Fox JG. Inflammation and cancer. I. Rodent models of infectious gastrointestinal and liver cancer. Am J Physiol Gastrointest Liver Physiol. 2004;286:G361–6.PubMedCrossRefGoogle Scholar
  41. 41.
    Rauws EA, Tytgat GN. Cure of duodenal ulcer associated with eradication of Helicobacter pylori. Lancet. 1990;335:1233–5.PubMedCrossRefGoogle Scholar
  42. 42.
    Graham DY, Lew GM, Klein PD, Evans DG, Evans DJ Jr, Saeed ZA, et al. Effect of treatment of Helicobacter pylori infection on the long-term recurrence of gastric or duodenal ulcer. A randomized, controlled study. Ann Intern Med. 1992;116:705–8.PubMedGoogle Scholar
  43. 43.
    Hopkins RJ, Girardi LS, Turney EA. Relationship between Helicobacter pylori eradication and reduced duodenal and gastric ulcer recurrence: a review. Gastroenterology. 1996;110:1244–52.PubMedCrossRefGoogle Scholar
  44. 44.
    Mocek FW, Ward WW Jr, Wolfson SE, Rumage WT Jr, Wieman TJ. Elimination of recurrent hyperplastic polyps by eradication of Helicobacter pylori. Ann Intern Med. 1994;120:1007–8.PubMedGoogle Scholar
  45. 45.
    Wotherspoon AC, Doglioni C, Diss TC, Pan L, Moschini A, de Boni M, et al. Regression of primary low-grade B-cell gastric lymphoma of mucosa-associated lymphoid tissue type after eradication of Helicobacter pylori. Lancet. 1993;342:575–7.PubMedCrossRefGoogle Scholar
  46. 46.
    Gasbarrini A, Franceschi F, Tartaglione R, Landolfi R, Pola P, Gasbarrini G. Regression of autoimmune thrombocytopenia after eradication of Helicobacter pylori. Lancet. 1998;352:878.PubMedCrossRefGoogle Scholar
  47. 47.
    Inaba T, Mizuno M, Take S, Suwaki K, Honda T, Kawai K, et al. Eradication of Helicobacter pylori increases platelet count in patients with idiopathic thrombocytopenic purpura in Japan. Eur J Clin Invest. 2005;35:214–9.PubMedCrossRefGoogle Scholar
  48. 48.
    Wedi B, Wagner S, Werfel T, Manns MP, Kapp A. Prevalence of Helicobacter pylori-associated gastritis in chronic urticaria. Int Arch Allergy Immunol. 1998;116:288–94.PubMedCrossRefGoogle Scholar
  49. 49.
    Dufour C, Brisigotti M, Fabretti G, Luxardo P, Mori PG, Barabino A. Helicobacter pylori gastric infection and sideropenic refractory anemia. J Pediatr Gastroenterol Nutr. 1993;17:225–7.PubMedCrossRefGoogle Scholar
  50. 50.
    de Vries AC, Kuipers EJ, Rauws EA. Helicobacter pylori eradication and gastric cancer: when is the horse out of the barn? Am J Gastroenterol. 2009;104:1342–5.PubMedCrossRefGoogle Scholar

Copyright information

© Springer 2010

Authors and Affiliations

  • Susumu Take
    • 1
    • 3
  • Motowo Mizuno
    • 2
  • Kuniharu Ishiki
    • 3
  • Tomowo Yoshida
    • 3
  • Nobuya Ohara
    • 4
  • Kenji Yokota
    • 5
  • Keiji Oguma
    • 5
  • Hiroyuki Okada
    • 6
  • Kazuhide Yamamoto
    • 6
  1. 1.Department of Internal MedicineFukuwatari Municipal HospitalOkayamaJapan
  2. 2.Department of Gastrointestinal EndoscopyHiroshima City HospitalHiroshimaJapan
  3. 3.Department of Internal MedicineNippon Kokan Fukuyama HospitalFukuyamaJapan
  4. 4.Department of PathologyOkayama University Graduate School of Medicine, Dentistry and Pharmaceutical SciencesOkayamaJapan
  5. 5.Department of BacteriologyOkayama University Graduate School of Medicine, Dentistry and Pharmaceutical SciencesOkayamaJapan
  6. 6.Department of Medicine and Medical ScienceOkayama University Graduate School of Medicine, Dentistry and Pharmaceutical SciencesOkayamaJapan

Personalised recommendations